Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011
|
|
- Philomena Malone
- 5 years ago
- Views:
Transcription
1 Lipid Studies That Rocked My World Gabor Gyenes Medicine Grand Rounds May 27, 2011
2 Disclosure of Conflicts of Interest I have received travel grants and honoraria from sanofi-aventis, Pfizer, Servier, Merck, Procter & Gamble, Biovail, AstraZeneca, Medtronic, Novartis, Boehringer-Ingelheim and Merck/Frosst/Schering No stocks or bonds, unfortunately I was the Primary Investigator of studies sponsored by Pfizer, Boehringer- Ingelheim, sanofi-aventis, and currently, GSK
3 Objectives Primary prevention JUPITER Secondary prevention PROVE-IT Meta-analysis 2010 How (un)well we do this U of A study You tell me what to do - ACTION
4 The Primary Prevention Study We d Love to Ignore MGR\Drops of Jupiter.mp4 Drops of JUPITER
5 JUPITER JUPITER was the first large study to examine the role of statin therapy in individuals with low to normal LDL-C levels (mean of 2.7 mm/l) but with elevated hscrp It assessed the long-term impact of rosuvastatin 20 mg/d in individuals who, based on Framingham risk scores, did not qualify for lipid-lowering treatment according to current guidelines Does elevated hscrp identify a patient who would benefit from statin therapy? Ridker P et al. N Eng J Med 2008;359:
6 CRP contributes to all stages of atherosclerosis Roles of CRP Endothelial Dysfunction Vasodilation NO Endothelial activation Monocyte adhesion Endothelial progenitor cells Plaque progression Monocyte migration VSMC proliferation Plaque Rupture /Thrombosis Cap thinning TF secretion Fibrinolysis Progression of atherosclerosis NO: Nitric oxide, VSMC: Vascular Smooth Muscle Cell, TF: Tissue factor Bisoendial RJ, Kastelein JJP, Stroes ESG. Atherosclerosis 2007; 195:e10-18 Packard RRS, Libby P. Clin Chem 2008; 54:24-38 For complete therapeutic and safety information please consult the CRESTOR Product Monograph.
7 Cardiovascular event-free survival in women using combined LDL-C and CRP measurements 1.00 Probability of eventfree survival Low LDL-C, low CRP High LDL-C, low CRP Low LDL-C, high CRP High LDL-C, high CRP Women s Health Study data LDL-C=low-density lipoprotein cholesterol; CRP=C-reactive protein Median LDL-C=3.2 mmol/l (124 mg/dl) Median CRP=1.5 mg/l Ridker PM et al. N Engl J Med 2002; 347:
8 JUPITER study design No history of CAD men 50 yrs women 60 yrs LDL-C <3.36 mmol/l CRP 2.0 mg/l Placebo run-in Rosuvastatin 20 mg (n~8900) Placebo (n~8900) Visit: Week: month intervals Final 3 4 y Lead-in/ eligibility Randomisation Lipids CRP Tolerability Lipids CRP Tolerability Lipids CRP Tolerability HbA 1C Primary Endpoint was the composite of: cardiovascular death, stroke, MI, unstable angina and arterial revascularisation
9 JUPITER - Baseline laboratory parameters * Rosuvastatin Placebo n=8901 n=8901 Total cholesterol (mg/dl) 4.81 ( ) 4.78 ( ) LDL cholesterol (mg/dl) 2.69 ( ) 2.69 ( ) HDL cholesterol (mg/dl) 1.27 ( ) 1.27 ( ) Triglycerides (mg/dl) 1.33 ( ) 1.33 ( ) hscrp (mg/l) 4.2 ( ) 4.3 ( ) Glucose (mg/dl) 5.88 ( ) 5.88 ( ) HbA 1c (%) 5.7 ( ) 5.7 ( ) Glomerular filtration rate, (ml/min/1.73m 2 ) 73.3 ( ) 73.6 ( ) For hscrp, values are the average of the values obtained at two screening and visits *All values are median (interquartile range) or N (%). Ridker P et al. N Eng J Med 2008;359: For complete therapeutic and safety information please consult the CRESTOR Product Monograph.
10 JUPITER - Primary Endpoint Time to first occurrence of a CV death, non-fatal stroke, non-fatal MI, unstable angina or arterial revascularization Percent of patients with primary endpoint Hazard Ratio 0.56 (95% CI ) P< Placebo Years Number at risk RSV Placebo Rosuvastatin 20 mg NNT for 2y = 95 5y* = 25 *Extrapolated figure based on Altman and Andersen method Ridker P et al. N Eng J Med 2008;359:
11 JUPITER - Total Mortality Death from any cause Percent total mortality Hazard Ratio 0.80 (95% CI ) p=0.02 Placebo Rosuvastatin 20mg Years Number at risk RSV Placebo Ridker P et al. N Eng J Med 2008;359:
12 JUPITER Effects on LDL-C, HDL-C, TG and hscrp at 12 months; Percentage change between rosuvastatin and placebo 10 LDL-C HDL-C TG hscrp Percentage change from baseline (%) % p< % p<0.001* 17% p< % p<0.001 *P-value at study completion (48 months) = 0.34 Ridker P et al. N Eng J Med 2008;359:
13 JUPITER Tolerability and safety data Placebo [n=8901] Rosuvastatin p-value [n=8901] Adverse Events, (%) Any serious adverse event Muscle weakness, stiffness, pain Myopathy Rhabdomyolysis 0.0 <0.1 * ---- Newly diagnosed cancer Death from cancer Gastrointestinal disorders Renal disorders Bleeding Hepatic disorders Other events, (%) Newly diagnosed diabetes ** Haemorrhagic stroke *Occurred after trial completion; **physician reported newly diagnosed diabetes Ridker P et al. N Eng J Med 2008;359:
14 JUPITER summary and perspectives In these patients with normal LDL-C and elevated CRP levels the administration of Crestor 20 mg/d resulted in: A 50% LDL-reduction A 44% reduction in the primary endpoint of major cardiovascular events A 20% reduction in total mortality (p=0.02) And it was well tolerated This is a public health policy issue: how much are we willing to pay to prevent one CV event in an already low risk population? Screening plus treatment costs However, we need to offer CRP screening to these individuals if they re willing to take a statin long-term
15 SECONDARY PREVENTION MGR\The hardest part.mp4
16 The Paradigm Shift: PROVE-IT-TIMI pts w/ ACS randomized to pravastatin 40mg vs. atorvastatin 80mg Pravastatin arm achieved then current Guideline recommendations at LDL<2.5 mm/l Lipitor arm achieved median LDL of 1.6 mm/l, or an on-treatment mean of 1.8 D/MI/UA/revascularization: 16% RRR (p = 0.005) in 2 years The price: 3.3% vs. 2.7% LFT NEJM 2004;350:1495.
17 Reasons Why PROVE-IT Convinced Me The study was designed to show non-inferiority of pravachol It was sponsored by BMS not Pfizer Not placebo-controlled yet so significant results REVERSAL (similarly designed IVUS study) showed vascular benefits although only in those w/ LDL<1.8 NEJM 2004;350:1495.
18 Updated Cholesterol Treatment Trialist s (CTT) Meta-analysis Meta-analyses of individual participant data; A) 5 studies of less vs. more intensive statin therapy; w/ >1,000 participants (39,612); >2 yrs F/U (5.1 yrs) B) 21 studies (129,526 pts) of statin therapy vs. placebo w/ 4.8 yrs of mean F/U Calculated the average risk reduction and the ARR/1 mm/l at one year as well Safety data were also reported Lancet 2010; 376:
19 CTT Meta-analysis A 0.51 mm/l further LDL-reduction (in the first year) resulted in: 15% (p<0.0001) RRR of vascular events incl. 13% RRR of coronary death or non-fatal MI (p<0.0001) 19% RRR in coronary revascularisation (p<0.0001), 16% RRR in ischemic stroke (p=0.005) The per mm/l reductions were similar to those in the B trials so they were all combined for further analysis: a 22% reduction of major vascular events/1.0 mm/l LDL-C reduction was found in all patients including those with LDL<2 mm/l on the less intensive or control regimen Lancet 2010; 376:
20 Combined Results - 2 All-cause mortality was reduced by 10%/ 1.0 mm/l LDL reduction mainly d/t reductions in CHD deaths (RR 0.80, 99% CI ; p<0.0001) no significant effect on deaths d/t stroke or other vascular causes No effects on deaths due to cancer, other non-vascular causes or on cancer incidence, even at low LDL levels NS excess of hemorrhagic stroke (257 vs. 220; RR 1.12, 95% CI ; p=0.2.) 10 (of 14 altogether) rhabdo cases w/ Zocor 80! Lancet 2010; 376:
21 Practical Consequences This should be convincing enough to us who initiate treatment for the high-risk patients that we should follow the ALARA rule To me this means that in pts w/ vascular disease I must initiate Lipitor 80mg (maybe Crestor 40mg) therapy in hospital because a lower dose means intentional under treatment that would disadvantage the patient long-term the dose will never be uptitrated So how well do we do this?
22 The Application of Knowledge MGR\DT A nightmare to remember.mp4
23 Intensive Statin Therapy (IST) in Acute Coronary Syndrome Patients Admitted to a Tertiary Care Centre: Current Practice Pattern Evaluation Jennifer R. Shiu, BScPharm 1, Glen J. Pearson, BSc, BScPharm, PharmD, FCSHP 2, Theresa L. Charrois, BScPharm, MSc, ACPR 2, Gabor Gyenes, MD, PhD 2, Sheri L. Koshman, BScPharm, PharmD, ACPR 2 1 Regional Pharmacy Services, Alberta Health Services; 2 Division of Cardiology; University of Alberta, Edmonton, AB
24 Methods Retrospective chart review of randomly selected ACS (ICD 20 25) patients in hospital and in early follow up after discharge Conducted in 2 phases at the University of Alberta Hospital (UAH) in Edmonton, AB Phase 1: retrospective chart review of ACS patients admitted Phase 2: chart review of cardiologist follow up clinic letters in patients started on IST during hospitalization
25 Methods Inclusion Criteria Adults admitted to cardiology wards at UAH between November 1, 2007 and October 31, 2008 with a most responsible diagnosis of an ACS Phase 2: Started on IST (atorvastatin 80 mg or simvastatin 80 mg) during hospitalization Exclusion Criteria Transferred to another hospital Admitted or transferred to CV surgery wards Death during index hospitalization Phase 2: Not followed by a cardiologist at UAH on discharge summary No scheduled follow up cardiologist visit on discharge summary
26 Table 2: Statin Utilization Patterns (n = 111) IST (%) Other Statin/ No IST (%) No Statin (%) Prior to Admission* 7 (6.3) 45 (40.5) 59 (53.2) At Discharge 53 (47.7) 50 (45.0) 8 (7.2) The mean atorvastatin equivalent dose at discharge was 33 mg. * Assumed 3 patients without statin doses documented PTA were not IST
27 Figure 3: Phase 2 Results Newly Discharged on IST The most common reason for IST DC at F/U was elevated LFT. However, no LFT elevation was >3x ULN.
28 Conclusions Overall, the majority of post ACS patients are treated with statins (93%) However, IST utilization (52%) in the post ACS population appears to be suboptimal in eligible patients Newly initiated IST shows poor persistence in follow up after discharge, even though most patients remain on a statin Reasons for this treatment gap need to be further elucidated
29 My Conclusions Registry studies and our own experience shows that we are disadvantaging our patients by not even trying to use the highest dose of potent statins This practice also sends the wrong message across if we are afraid of using the highest dose others will be too Think of other fields (HTN, HF, etc.) where we ve been through these problems and the resolution has always been that we started to do what s right and everyone else followed suit
30 The Most Recent Sh(R)ocks A trial of extended-release niacin (Niaspan, Abbott) given in addition to statin therapy has been halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population. AIM-HIGH was a five-year study of almost 3500 patients. The DSMB concluded that "high-dose, extendedrelease niacin offered no benefits beyond statin therapy alone in reducing cardiovascular-related complications in this trial. The rate of clinical events was the same in both treatment groups, and there was no evidence that this would change by continuing the trial."
31 Further Failures Fibrates have no significant outcome benefit, maybe up to 10% by the most optimistic study Torcetrapib: increases mortality and ineffective in decreasing CIM thickness Dalcetrapib: no improvement in endothelial fx n Ezetrol: still no positive data although its negative trials should be dismissed Omega-3 FAs added to statins: no effect Bottom line: we have no alternatives to statins
32 What Should We Do? We need ACTION!!! MGR\Action.mp4 The SWEET
33 Heart Protection Study: Safety Placebo Simvastatin (n=10,267) (n=10,269) P Value Liver ALT 32 (0.31%) 43 (0.42%) NS >4x ULN Muscle CK 6 (0.06%) 11 (0.11%) NS >10x ULN Myalgia/6 mo ~6-7% (Σ32.9%) ~6-7% (Σ:33.2%) NS Cancer deaths 345 (3.4%) 359 (3.5%) NS Heart Protection Study Collaborative Group. Lancet. 2002;360:7-22.
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationNICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant
NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background
More informationAIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)
AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5) Jacques Genest MD Cardiovascular Research Laboratory McGill University Health Center Disclosure J. Genest MD 2012 Advisory Board, Speaker s Bureau, Consultant,
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationCanakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationCholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia
Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationTop 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008
Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationIs it an era for statin for life?
Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationCETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia
CETP inhibition: pros and cons Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies or membership of advisory boards from:
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationThe Target is LDL, HDL not so much
The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationExpert Meeting on Large Simple Trials (LST s)
Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationSafety of Lipid-lowering Drugs Frank Ruschitzka, MD, FRCP Professor of Cardiology Head, Heart Failure/Transplantation University Clinic Zurich
Safety of Lipid-lowering Drugs Frank Ruschitzka, MD, FRCP Professor of Cardiology Head, Heart Failure/Transplantation University Clinic Zurich Conflict of interest: Bayer, Biomarin, Biotronik, Cardiorentis,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationREAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease
REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationSubodh Verma, MD PhD FRCSC
CIRT and CANTOS Targeting g Inflammation at in Atherosclerosis e s Subodh Verma, MD PhD FRCSC Cardiac Surgeon, St. Michael s Hospital Associate Professor, Surgery & Pharmacology Canada Research Chair in
More informationNew Horizons in Dyslipidemia Management in Primary Care
New Horizons in Dyslipidemia Management in Primary Care Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationAtherosclerosis Regression An Overview of Recent Findings & Issues
Atherosclerosis Regression An Overview of Recent Findings & Issues 13th Angioplasty Summit 2008 Cheol Whan Lee, MD University of Ulsan, Asan Medical Center, Seoul, Korea CardioVascular Research Foundation
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More information